合并症对系统硬化症患者死亡率的影响。

IF 5.1 2区 医学 Q1 RHEUMATOLOGY
Thomas Fauthoux, Damien Brisou, Estibaliz Lazaro, Julien Seneschal, Joel Constans, Sophie Skopinski, Pierre Duffau, Elodie Blanchard, Cécile Contin-Bordes, Thomas Barnetche, Marie-Elise Truchetet
{"title":"合并症对系统硬化症患者死亡率的影响。","authors":"Thomas Fauthoux, Damien Brisou, Estibaliz Lazaro, Julien Seneschal, Joel Constans, Sophie Skopinski, Pierre Duffau, Elodie Blanchard, Cécile Contin-Bordes, Thomas Barnetche, Marie-Elise Truchetet","doi":"10.1136/rmdopen-2024-004637","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Systemic sclerosis (SSc) is a serious life-threatening tissue disease. A significant aspect of its mortality arises from comorbid conditions. Our study aimed at mapping out the prevalence of these comorbidities and their relation to mortality, thus creating a 'comorbidome'.</p><p><strong>Methods: </strong>In our retrospective, single-centre observational study, we recorded each patient's data, including demographic informations, vital stats and SSc-related organ involvement, along with the presence or absence of 14 predefined comorbidities. We also documented the dates of their initial and most recent visits. To construct survival curves, we used the Kaplan-Meier method, followed by a Cox regression model for multivariate analysis.</p><p><strong>Results: </strong>Our study involved 400 participants, 74 of whom unfortunately passed away. It is important to note that three specific comorbidities showed significant correlation to mortality: neoplasia, cardiovascular diseases and polypharmacy, as well as two SSc-specific organ involvements (lung and cardiac).</p><p><strong>Conclusion: </strong>Our research led to the successful creation of the SSc comorbidome. Comorbidities are a major concern for patients suffering from SSc, particularly cardiovascular diseases and neoplasms. Our study highlights the effects of polypharmacy. The resultant comorbidome offers a comprehensive and analytical perspective on this complex issue and underscores the inter-relatedness of the data. Our study, however, was limited by a small sample size. Therefore, to confirm our findings, validation on a larger scale is necessary. This could potentially contribute to the creation of a future mortality scoring tool.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492939/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comorbidity burden on mortality in patients with systemic sclerosis.\",\"authors\":\"Thomas Fauthoux, Damien Brisou, Estibaliz Lazaro, Julien Seneschal, Joel Constans, Sophie Skopinski, Pierre Duffau, Elodie Blanchard, Cécile Contin-Bordes, Thomas Barnetche, Marie-Elise Truchetet\",\"doi\":\"10.1136/rmdopen-2024-004637\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Systemic sclerosis (SSc) is a serious life-threatening tissue disease. A significant aspect of its mortality arises from comorbid conditions. Our study aimed at mapping out the prevalence of these comorbidities and their relation to mortality, thus creating a 'comorbidome'.</p><p><strong>Methods: </strong>In our retrospective, single-centre observational study, we recorded each patient's data, including demographic informations, vital stats and SSc-related organ involvement, along with the presence or absence of 14 predefined comorbidities. We also documented the dates of their initial and most recent visits. To construct survival curves, we used the Kaplan-Meier method, followed by a Cox regression model for multivariate analysis.</p><p><strong>Results: </strong>Our study involved 400 participants, 74 of whom unfortunately passed away. It is important to note that three specific comorbidities showed significant correlation to mortality: neoplasia, cardiovascular diseases and polypharmacy, as well as two SSc-specific organ involvements (lung and cardiac).</p><p><strong>Conclusion: </strong>Our research led to the successful creation of the SSc comorbidome. Comorbidities are a major concern for patients suffering from SSc, particularly cardiovascular diseases and neoplasms. Our study highlights the effects of polypharmacy. The resultant comorbidome offers a comprehensive and analytical perspective on this complex issue and underscores the inter-relatedness of the data. Our study, however, was limited by a small sample size. Therefore, to confirm our findings, validation on a larger scale is necessary. This could potentially contribute to the creation of a future mortality scoring tool.</p>\",\"PeriodicalId\":21396,\"journal\":{\"name\":\"RMD Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492939/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"RMD Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/rmdopen-2024-004637\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMD Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/rmdopen-2024-004637","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言系统性硬化症(SSc)是一种严重威胁生命的组织疾病。其死亡率的一个重要方面来自合并症。我们的研究旨在了解这些合并症的发病率及其与死亡率的关系,从而建立一个 "合并症组":在我们的回顾性单中心观察研究中,我们记录了每位患者的数据,包括人口统计学信息、生命统计和 SSc 相关器官受累情况,以及是否存在 14 种预定义的合并症。我们还记录了患者初次就诊和最近一次就诊的日期。为了绘制生存曲线,我们使用了卡普兰-梅耶法,然后使用 Cox 回归模型进行多变量分析:我们的研究涉及 400 名参与者,其中 74 人不幸去世。值得注意的是,三种特定的合并症与死亡率有显著相关性:肿瘤、心血管疾病和多重药物治疗,以及两种 SSc 特定器官(肺部和心脏)受累:结论:我们的研究成功地创建了SSc合并症组。合并症是SSc患者的主要担忧,尤其是心血管疾病和肿瘤。我们的研究强调了多药治疗的影响。由此得出的合并症组为这一复杂问题提供了一个全面的分析视角,并强调了数据的相互关联性。然而,我们的研究受到样本量较小的限制。因此,为了证实我们的研究结果,有必要进行更大规模的验证。这有可能有助于创建未来的死亡率评分工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comorbidity burden on mortality in patients with systemic sclerosis.

Introduction: Systemic sclerosis (SSc) is a serious life-threatening tissue disease. A significant aspect of its mortality arises from comorbid conditions. Our study aimed at mapping out the prevalence of these comorbidities and their relation to mortality, thus creating a 'comorbidome'.

Methods: In our retrospective, single-centre observational study, we recorded each patient's data, including demographic informations, vital stats and SSc-related organ involvement, along with the presence or absence of 14 predefined comorbidities. We also documented the dates of their initial and most recent visits. To construct survival curves, we used the Kaplan-Meier method, followed by a Cox regression model for multivariate analysis.

Results: Our study involved 400 participants, 74 of whom unfortunately passed away. It is important to note that three specific comorbidities showed significant correlation to mortality: neoplasia, cardiovascular diseases and polypharmacy, as well as two SSc-specific organ involvements (lung and cardiac).

Conclusion: Our research led to the successful creation of the SSc comorbidome. Comorbidities are a major concern for patients suffering from SSc, particularly cardiovascular diseases and neoplasms. Our study highlights the effects of polypharmacy. The resultant comorbidome offers a comprehensive and analytical perspective on this complex issue and underscores the inter-relatedness of the data. Our study, however, was limited by a small sample size. Therefore, to confirm our findings, validation on a larger scale is necessary. This could potentially contribute to the creation of a future mortality scoring tool.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
RMD Open
RMD Open RHEUMATOLOGY-
CiteScore
7.30
自引率
6.50%
发文量
205
审稿时长
14 weeks
期刊介绍: RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信